Intuitive Surgical reported strong Q2 earnings with adjusted EPS of $2.80, surpassing analyst expectations due to high demand for its da Vinci robotic surgical systems. Despite the positive results, the stock dropped 12% in premarket trading after the company issued a full-year procedure growth forecast below investor expectations. Analyst Raymond James kept an "Outperform" rating but lowered the price target from $577 to $483, reflecting tempered future growth predictions. The stock currently trades around $402, down from a 52-week high of $603.88, highlighting market concerns over slower growth despite solid earnings.
Intuitive Surgical reported strong Q2 2026 results, with EPS of $2.80 beating estimates by nearly 13% and revenue reaching $2.89 billion, surpassing forecasts. This marks the fourth consecutive quarter the company has exceeded earnings expectations, ...
Intuitive Surgical announced a 19% revenue increase to $2.89 billion in Q2 2026, driven by a 16% rise in worldwide procedures and higher system placements. The company placed 468 da Vinci surgical systems, including 246 da Vinci 5 models, and grew it...
Intuitive Surgical is scheduled to release its Q2 2026 earnings report, with analysts forecasting an EPS of $2.48 and revenue of $2.83 billion, up from $2.44 billion last year. The company is known for its da Vinci robotic surgical systems and has a ...
In Q2 2026, AMD's stock surged 182.4%, driven by growth in AI workloads linked to large language models. CrowdStrike also saw strong gains of 95.6% due to a positive shift in the AI investment narrative. Conversely, Netflix's stock declined after bea...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
